Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
Details of the poster presentations are as follows:
Title: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGF-β inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (cSCC)
Published Abstract #: CT034
Session Category: Clinical Trials
Session Title: Phase 0 and Phase I Clinical Trials
Session Date and Time: 4/28/2025 9:00 a.m. CT
Location: McCormick Place Convention Center, Poster Section 49
This presentation will highlight data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC patients.
Title: Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with Pembrolizumab
Published Abstract #: 3284
Session Category: Clinical Research
Session Title: Modifiers of the Tumor Microenvironment
Session Date and Time: 4/28/2025 2:00 p.m. CT
Location: McCormick Place Convention Center, Poster Section 30
This presentation will highlight a translational medicine biomarker dataset that provides insights into the effects of targeted inhibition of TGF-β with ficerafusp alfa.
Title: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors
Published Abstract #: 4434
Session Category: Experimental and Molecular Therapies
Session Title: Reversal of Drug Resistance
Session Date and Time: 4/29/2025 9:00 a.m. CT
Location: McCormick Place Convention Center, Poster Section 23
This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.
Following the meeting, the poster presentations will be available on Bicara's website at www.bicara.com.
About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara's lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Bicara's preclinical studies and presentation of results, the clinical development of ficerafusp alfa and presentation of data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC, clinical development of ficerafusp alfa in combination with pembrolizumab, the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy and tolerability. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct and enrollment of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials and regulatory developments in the United States and foreign countries, whether Bicara's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara's filings with the Securities and Exchange Commission (SEC), including Bicara's Quarterly Report on Form 10-Q for the period ended September 30, 2024, as well as any subsequent filings that Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara's views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Contacts
InvestorsRachel FrankIR@bicara.com
MediaDan Budwick1ABdan@1abmedia.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
InStride Redefines Workforce Development Through Strategic Expansion
Empowering businesses with strategic education and skilling solutions that unlock career advancement and organizational impact LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- InStride, a leading provider of strategic education and skilling solutions, today announced continued growth, accelerated by its new and transformative approach to workforce development. Recently named by TIME and Statista as one of the World's Top EdTech Companies of 2025, InStride has advanced its offerings to address critical talent challenges through education and skilling solutions designed to be career-aligned, industry-relevant, and tailored to its corporate partners' needs. In partnership with some of the most influential organizations in the Fortune 250, InStride provides nearly one million eligible employees access to over 2,500 education opportunities, helping prevent $73 million in student loan debt to date. 'Education benefits have come a long way from basic tuition reimbursement,' said Craig Maloney, CEO of InStride. 'We've reimagined them as strategic levers for HR teams to attract and retain talent, upskill their workforce, fill critical roles, and ensure their people are ready for what's next. Over the past six years, we've built programs that address such challenges and have seen the difference they can make for people and businesses alike.' Each of the following innovations was designed to make strategic education solutions more relevant, flexible, and effective—for the people using them and the companies supporting them. Award-winning, expanded offerings A broader, more flexible learning networkGone are the days of a one-size-fits-all workforce development. InStride's expanding portfolio of 2,500+ educational offerings with leading universities, such as Arizona State University, creates flexible pathways aligned with workforce demands. Formats include English-language programs, specialized healthcare certifications, and stackable credentials, all tailored to how people learn and grow. Career Education PathsInStride's award-winning Career Education Paths connect learning directly to career outcomes, increasing program completion rates. Honored by Fast Company and EdTech Breakthrough Awards, these structured paths are designed using Lightcast to map learning to 40+ specific roles across technology, healthcare, and corporate services. The result: higher engagement and a reliable pipeline of skilled talent. Dependent education benefitsInStride enables businesses to extend education benefits to employees' dependents. This allows employees at participating companies to use their benefits for spouses and children who gain access to career-aligned courses, certifications, and degrees, which enhances employee loyalty and retention as workers feel a deeper commitment to companies investing in their families. In turn, dependent benefits create a ripple effect beyond the workplace, helping to uplift communities by expanding access to education and opportunity for future generations. Supporting a skills-first approachInStride helps companies build talent strategies grounded in employee skills and capabilities. This includes helping companies identify the skills needed for key roles, map career paths, and uncover gaps between the skills employees have and the ones their businesses need. With that foundation in place, companies can make more informed hiring and promotion decisions—and use targeted learning programs to help employees build the skills to grow into critical roles. Pioneering, scalable, customizable solutions Hybrid clinical cohortsHealthcare systems can't rely solely on external hiring. InStride's hybrid clinical cohorts address staffing shortages in healthcare by combining online coursework with in-hospital training. With structured learning models to boost completion rates, they create pathways to in-demand roles like medical assistants, surgical technologists, and clinical lab specialists. This empowers employers to develop talent from within, which has proven to reduce staffing shortages and improve career mobility for existing employees. Industry-first franchise workforce education modelInStride's hub-and-spoke franchise education model allows franchisees to opt into and manage corporate education programs while customizing them for their workforce, providing centralized tracking and reporting tools for improved oversight. This balance between corporate structure and local flexibility helps franchise businesses retain and develop talent while maintaining a consistent workforce strategy. This approach has delivered impressive results, with over 50% of franchisees at one partner adopting the program in its first year and achieving a one-third higher retention rate for participating employees compared to non-participants. Custom solutions for accelerated capability buildingTo help businesses build specialized professional skill sets, InStride introduced Capability Accelerators, which provide custom academies tailored for specific roles including first-line managers, manufacturing and healthcare leaders; cohort-based learning with applied, real-world training featuring expert coaching and AI-enhanced tools; and university-backed content that blends academic insights with practical, job-relevant learning. 'We remain committed to building solutions that meet real workforce needs,' said Craig Maloney, CEO of InStride. He says of the company's future development: 'We're now investing more in AI that truly transforms individual careers and organizational success. We always start with our partners' business goals in mind—and by intelligently analyzing employee data like job roles, skills, and aspirations, we're better able to connect talent to the right education opportunities and personalized coaching support. That precision is what drives meaningful outcomes.'InStride solves corporate talent challenges with strategic education and skilling solutions. By breaking down barriers to learning, fostering career growth aligned with organizational goals, and simplifying program management, InStride delivers lasting impact. Partnering with forward-thinking companies like Labcorp, Adidas, and SSM Health, InStride drives meaningful social and business outcomes by providing access to life-changing education. Visit or follow InStride on LinkedIn for more information and up-to-date news. ContactSophia Puglisi, Communications Manager at InStride, 805-889-6273Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
High Purity Quartz (HPQ) Market Research 2025-2032: Industry Analysis, Size, Shares, Growth, Trends, and Market Forecasts
Growing Demand and a Maturing Technological Landscape That is Fostering Scalability and Affordability in HPQ Production Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "High Purity Quartz Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Form, End Use, Distribution Channel, Geographic Coverage and By Company)" report has been added to global high purity quartz (HPQ) market is poised for notable expansion, projected to grow from US$ 868.9 Mn in 2025 to an estimated US$ 1.38 billion by 2032. This promising growth trajectory, marked by a steady CAGR of 6.9%, is underpinned by increasing demand from key industries such as semiconductors, solar energy, and Market DriversOne of the key forces propelling the HPQ market is the surge in solar panel installations across emerging markets. In 2023 alone, global solar additions reached 447 GW, pushing total capacity to 1.6 TW. China alone contributed 253 GW, highlighting its dominance in global solar adoption. This rising emphasis on renewable energy infrastructure is directly fueling the demand for HPQ, particularly in the manufacturing of ultra-pure silicon wafers for photovoltaic the relentless expansion of the semiconductor sector continues to generate demand for high-grade quartz. With growing applications in AI, IoT, autonomous vehicles, and advanced consumer electronics, the semiconductor industry's need for defect-free materials like HPQ remains strong. The telecom and optics industry, too, is emerging as a growth driver, requiring ultra-pure quartz for high-performance fiber optic cables and optical OpportunityTechnological advancements are creating substantial opportunities in the HPQ market. Innovations in purification techniques - including plasma-based refinement, hydrothermal processing, and AI-enabled quality control - are significantly reducing production costs while maintaining ultra-high purity. Companies adopting automated purification processes and modern leaching methods are managing to reduce energy consumption and waste, thereby making HPQ more accessible to broader use of advanced monitoring systems allows for better yield, consistency, and cost-efficiency, particularly in achieving grades beyond 99.995% purity. As a result, new entrants and regional players are finding feasible entry points into the market, intensifying competition and expanding supply networks. These trends signal not only growing demand but also a maturing technological landscape that is fostering scalability and affordability in HPQ ChallengesDespite its promising growth outlook, the HPQ market faces certain hurdles. The primary challenge lies in the high cost of achieving ultra-pure quartz through complex purification processes such as thermal treatment, chemical leaching, and filtration. These methods are both energy-intensive and expensive, requiring significant capital the availability of raw materials is constrained by the limited number of high-quality quartz deposits globally. Key sources include regions in the United States (notably Spruce Pine, North Carolina), Norway, and Australia. The geographical concentration of these reserves makes the market vulnerable to supply disruptions, such as the impact of Hurricane Helene on Spruce Pine's mining operations in 2024. Limited production capacity, coupled with high operational costs, continues to hamper broader market AnalysisThe Asia Pacific region stands out as the largest consumer of high purity quartz, driven by robust growth in both semiconductor manufacturing and solar energy adoption. Countries like China, South Korea, Japan, and Taiwan are global leaders in chip production and solar panel manufacturing. Notable investments such as Micron Technology's US$ 825 million semiconductor facility in India illustrate the region's long-term commitment to electronic manufacturing and renewable energy, thus reinforcing demand for Europe, the high purity quartz market is buoyed by the region's aggressive renewable energy targets. The European Union's goal for solar to account for 20% of electricity generation has catalyzed solar panel manufacturing, with countries such as Germany, France, and the UK leading the charge. A notable 26% increase in solar photovoltaic generation in 2022 illustrates the continent's rising dependence on HPQ for clean energy America, meanwhile, holds a pivotal position in HPQ production, thanks to the world-renowned Spruce Pine mines in North Carolina. This region supplies up to 90% of the globe's ultra-pure quartz. The geological uniqueness of Spruce Pine ensures unmatched purity, positioning North America as a strategic supplier, especially to the global semiconductor industry. Investment efforts by companies such as Sibelco to expand production capacities are expected to reinforce the region's Players The global HPQ market is characterized by the presence of several key players that are focused on research, capacity expansion, and strategic collaborations. These include: Sibelco High Purity Quartz Pty. Ltd. Creswick Quartz The Quartz Corporation Nordic Mining ASA Momentive Performance Materials Inc. Australian Silica Quartz Group Ltd. Fineton Development Limited Solar Quartz Technologies Companies are increasingly investing in R&D to refine purification technologies and reduce production costs. At the same time, partnerships and joint ventures are being forged to secure raw material sources and expand into new geographical in September 2024, Global Surfaces FZE launched the Middle East's largest engineered surfaces facility in the UAE, while Rover Critical Minerals Corp. moved to acquire the Silicon Valley Silica Project in British Columbia, which is estimated to host over 12 kilometers of high-purity Expert's EyeMarket analysts emphasize that HPQ's pricing varies significantly by grade and application. For instance, quartz used in lighting applications can be priced around US$ 650 per ton, whereas Grade-1 for telecom and optics reaches US$ 5,000 per ton. The most premium grades - Grade-2 and Grade-3 - used in semiconductors and photovoltaic cells can fetch as much as US$ 20,000 per ton. This reflects the value of HPQ in critical applications and underscores the market's potential profitability. The global high purity quartz market is segmented as follows: By Grade HPQ Powder Grade I Grade II Grade III By Application Semiconductor Solar Lighting Telecom & Optics Microelectronics Others By Region North America Europe Asia Pacific Latin America The Middle East & Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
